Pfizer reveals its PD-1 secret
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
Glaxo’s growth problem
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
Why ipatasertib is not the Akt Astra wants to follow
The repeated failure of Roche’s ipatasertib increases the risk for Astrazeneca’s rival Akt inhibitor capivasertib.
Novo takes the plunge in Alzheimer’s
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
What the coming year might hold for biopharma
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Boston deadheads its Lotus
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
After six years Bellicum admits it’s not ready for prime time
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
